StockData
CMMBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Chemomab Therapeutics Ltd.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026
$1.17−0.09 (-7.51%)

Close on Oct 19, 2026

Market cap
$749.09M
P/E (TTM)
65.0
Dividend yield
–

Chemomab Therapeutics Ltd. revenue by segment

No segment breakdown reported

Chemomab Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.